Literature DB >> 1094949

Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.

R M Lumish, C W Norden.   

Abstract

Cinoxacin (compound 64716) is a synthetic organic acid with antibacterial activity against most aerobic gram-negative bacilli. Minimal inhibitory concentrations of cinoxacin (agar-dilution method) were determined for 419 strains. Escherichia coli was the most susceptible group of organisms. The majority of Klebsiella sp., Enterobacter sp., Proteus sp., and Serratia marcescens were inhibited by 8 mug of cinoxacin per ml. Pseudomonas aeruginosa and all gram-positive isolates tested were resistant to 64 mug or less of cinoxacin per ml. Zones of inhibition using a 30-mug disk correlated well with agar-dilution minimal inhibitory concentrations (r = -0.9). Cinoxacin was bactericidal when tested with inocula of 5 x 10(6) organisms per ml. Resistance to cinoxacin was readily developed in all three strains tested by serial passage on drug-containing agar. The in vitro properties of this agent were similar to those of nalidixic acid.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1094949      PMCID: PMC429096          DOI: 10.1128/AAC.7.2.159

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Antibacterial action of "broad-spectrum" penicillins, cephalosporins and other antibiotics against Gram-negative bacilli isolated from bacteremic patients.

Authors:  N H Steigbigel; C E McCall; C W Reed; M Finland
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

2.  Compound 64716, a new synthetic antibacterial agent.

Authors:  W E Wick; D A Preston; W A White; R S Gordee
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Bacteriologic and pharmacodynamic aspects of nalidixic acid.

Authors:  L H Harrison; C E Cox
Journal:  J Urol       Date:  1970-12       Impact factor: 7.450

5.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

  5 in total
  16 in total

1.  First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

Authors:  M Jonsson; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  Antibacterial activity of cinoxacin in vitro.

Authors:  H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

3.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

4.  [A comparison of cinoxacin and nalidixic acid in the treatment of chronic urinary tract infections].

Authors:  H Briedigkeit; R Schimmelpfennig; R Buder; K Precht; H Dröseler
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  Efficacy of cinoxacin in urinary tract infections.

Authors:  A P Panwalker; H Giamarellou; G G Jackson
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

6.  Comparative in vitro studies of cinoxacin, nalidixic acid, and oxolinic acid.

Authors:  R C Gordon; L I Stevens; C E Edmiston; K Mohan
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

7.  In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1976-07       Impact factor: 5.191

8.  Pharmacology of cinoxacin in humans.

Authors:  H R Black; K S Israel; R L Wolen; G L Brier; B D Obermeyer; E A Ziege; J D Wolny
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

9.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.